Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...
Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...
Cancer research, drug safety testing and ageing biology may all gain a major boost from a new fluorescent sensor developed at ...
Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...
Zacks Investment Research on MSN
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal
DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose ...
A breakthrough live-cell sensor makes DNA repair visible as it happens, unlocking new possibilities in biology and medicine.
Cancer research, drug safety testing and aging biology may all gain a major boost from a new fluorescent sensor developed at ...
Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...
Following Aqara and Meross, SwitchBot has announced a new presence sensor with light, PIR, and 60 GHz mmWave radar sensors to ...
Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, expectations were $0.57. Operator: Ladies and gentlemen, welcome to the DexCom Third ...
SAN DIEGO (AP) — SAN DIEGO (AP) — DexCom Inc. (DXCM) on Thursday reported third-quarter net income of $283.8 million. The San Diego-based company said it had net income of 70 cents per share. Earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback